Literature DB >> 6646897

Medium-chain acyl-CoA dehydrogenase deficiency in children with non-ketotic hypoglycemia and low carnitine levels.

C A Stanley, D E Hale, P M Coates, C L Hall, B E Corkey, W Yang, R I Kelley, E L Gonzales, J R Williamson, L Baker.   

Abstract

Three children in two families presented in early childhood with episodes of illness associated with fasting which resembled Reye's syndrome: coma, hypoglycemia, hyperammonemia, and fatty liver. One child died with cerebral edema during an episode. Clinical studies revealed an absence of ketosis on fasting (plasma beta-hydroxybutyrate less than 0.4 mmole/liter) despite elevated levels of free fatty acids (2.6-4.2 mmole/liter) which suggested that hepatic fatty acid oxidation was impaired. Urinary dicarboxylic acids were elevated during illness or fasting. Total carnitine levels were low in plasma (18-25 mumole/liter), liver (200-500 nmole/g), and muscle (500-800 nmole/g); however, treatment with L-carnitine failed to correct the defect in ketogenesis. Studies on ketone production from fatty acid substrates by liver tissue in vitro showed normal rates from short-chain fatty acids, but very low rates from all medium and long-chain fatty acid substrates. These results suggested that the defect was in the mid-portion of the intramitochondrial beta-oxidation pathway at the medium-chain acyl-CoA dehydrogenase step. A new assay for the electron transfer flavoprotein-linked acyl-CoA dehydrogenases was used to test this hypothesis. This assay follows the decrease in electron transfer flavoprotein fluorescence as it is reduced by acyl-CoA-acyl-CoA dehydrogenase complex. Results with octanoyl-CoA as substrate indicated that patients had less than 2.5% normal activity of medium-chain acyl-CoA dehydrogenase. The activities of short-chain and isovaleryl acyl-CoA dehydrogenases were normal; the activity of long-chain acyl-CoA dehydrogenase was one-third normal. These results define a previously unrecognized inherited metabolic disorder of fatty acid oxidation due to deficiency of medium-chain acyl-CoA dehydrogenase.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6646897     DOI: 10.1203/00006450-198311000-00008

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  49 in total

Review 1.  The clinical manifestation of MCAD deficiency: challenges towards adulthood in the screened population.

Authors:  Ulrich A Schatz; Regina Ensenauer
Journal:  J Inherit Metab Dis       Date:  2010-06-08       Impact factor: 4.982

2.  The orphan nuclear receptor estrogen-related receptor alpha is a transcriptional regulator of the human medium-chain acyl coenzyme A dehydrogenase gene.

Authors:  R Sladek; J A Bader; V Giguère
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

3.  Elevated plasma carnitine in the hepatic form of carnitine palmitoyltransferase-1 deficiency.

Authors:  C A Stanley; F Sunaryo; D E Hale; J P Bonnefont; F Demaugre; J M Saudubray
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

4.  Measurement of the acyl-CoA intermediates of beta-oxidation by h.p.l.c. with on-line radiochemical and photodiode-array detection. Application to the study of [U-14C]hexadecanoate oxidation by intact rat liver mitochondria.

Authors:  N J Watmough; D M Turnbull; H S Sherratt; K Bartlett
Journal:  Biochem J       Date:  1989-08-15       Impact factor: 3.857

5.  A carnitine/acylcarnitine translocase assay applicable to biopsied muscle specimens without requiring mitochondrial isolation.

Authors:  M S Murthy; V S Kamanna; S V Pande
Journal:  Biochem J       Date:  1986-05-15       Impact factor: 3.857

6.  Rhabdomyolysis and acute encephalopathy in late onset medium chain acyl-CoA dehydrogenase deficiency.

Authors:  W Ruitenbeek; P J Poels; D M Turnbull; B Garavaglia; R A Chalmers; R W Taylor; F J Gabreëls
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-02       Impact factor: 10.154

7.  Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency: diagnosis by acylcarnitine analysis in blood.

Authors:  J L Van Hove; W Zhang; S G Kahler; C R Roe; Y T Chen; N Terada; D H Chace; A K Iafolla; J H Ding; D S Millington
Journal:  Am J Hum Genet       Date:  1993-05       Impact factor: 11.025

8.  A rare disease-associated mutation in the medium-chain acyl-CoA dehydrogenase (MCAD) gene changes a conserved arginine, previously shown to be functionally essential in short-chain acyl-CoA dehydrogenase (SCAD).

Authors:  B S Andresen; P Bross; T G Jensen; V Winter; I Knudsen; S Kølvraa; U B Jensen; L Bolund; M Duran; J J Kim
Journal:  Am J Hum Genet       Date:  1993-09       Impact factor: 11.025

9.  Gas chromatography--mass spectrometry (GC--MS) diagnosis of two cases of medium chain acyl-CoA dehydrogenase deficiency.

Authors:  P Divry; C Vianey-Liaud; J Cotte
Journal:  J Inherit Metab Dis       Date:  1984       Impact factor: 4.982

10.  Fatty acyl-CoA dehydrogenase deficiency: enzyme measurement and studies on alternative metabolism.

Authors:  N Gregersen
Journal:  J Inherit Metab Dis       Date:  1984       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.